Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

BV-2 cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amyloid-β (2) Angiotensin Receptor (1) Bacterial (1) Cannabinoid Receptor (2) Cholinesterase (ChE) (1) COX (3) Cytochrome P450 (1) ERK (2) Fungal (1) GSK-3 (1) Interleukin Related (3) Isotope-Labeled Compounds (1) Keap1-Nrf2 (3) Leukotriene Receptor (1) mGluR (2) Microtubule/Tubulin (1) NF-κB (6) NO Synthase (10) NOD-like Receptor (NLR) (2) p38 MAPK (1) Parasite (1) PGE synthase (1) Pyruvate Kinase (1) Reactive Oxygen Species (1) TNF Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (29) Metabolic Disease (2) Neurological Disease (14)

By Targets:

Akt (2)

Amyloid-β (2)

Angiotensin Receptor (1)

Bacterial (1)

Cannabinoid Receptor (2)

Cholinesterase (ChE) (1)

COX (3)

Cytochrome P450 (1)

ERK (2)

Fungal (1)

GSK-3 (1)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (3)

Leukotriene Receptor (1)

mGluR (2)

Microtubule/Tubulin (1)

NF-κB (6)

NO Synthase (10)

NOD-like Receptor (NLR) (2)

p38 MAPK (1)

Parasite (1)

PGE synthase (1)

Pyruvate Kinase (1)

Reactive Oxygen Species (1)

TNF Receptor (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (29)

Metabolic Disease (2)

Neurological Disease (14)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N12525

Bartsioside	Others	Inflammation/Immunology
Bartsioside is an anti-inflammatory agent which can be extracted from C. deserticola. Bartsioside exerts no significant cytotoxicity under 40 μM to BV-2 cells .

HY-155572

Nrf2 activator-8	Keap1-Nrf2	Inflammation/Immunology
Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC₅₀=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation .

HY-N10066

Anti-inflammatory agent 5	Others	Inflammation/Immunology
Anti-inflammatory agent 5 displays potent inhibition of NO generation in lipopolysaccharide-induced BV-2 microglial cells.

HY-N3760

Dimeric coniferyl acetate	NO Synthase	Inflammation/Immunology
Dimeric coniferyl acetate is a NO production inhibitor with an IC₅₀ value 7.9 μM in BV-2 microglial cells .

HY-147811

Heterophdoid A	NO Synthase COX Reactive Oxygen Species	Inflammation/Immunology
Heterophdoid A (Compound 1) is an anti-inflammatory agent. Heterophdoid A inhibits NO production with an IC₅₀ of 5.93 μM in BV-2 cells .

HY-N11945

Schiarisanrin A Kadsulignan J	NO Synthase	Others
Schiarisanrin A (Kadsulignan J) is a lignan with inhibitory activity on NO production. Schiarisanrin A inhibits NO production in BV-2 cells with an IC₅₀ of 9.6 μM .

HY-N10119

Ganoderterpene A	p38 MAPK	Neurological Disease
Ganoderterpene A attenuates LPS-induced inflammation and apoptosis via suppressing MAPK and TLR-4/NF-κB pathways in BV-2 cells.

HY-N8631

O-Acetylschisantherin L Acetylschisantherin L	NO Synthase	Inflammation/Immunology
O-Acetylschisantherin L (Acetylschisantherin L) is a natural lignan, which exhibits inhibitory effects on LPS-induced NO production in BV-2 cells with an IC₅₀ of 23.1 μM .

HY-N11943

Kadsulignan H	NO Synthase	Others
Kadsulignan H (compound 13) is a lignan with inhibitory activity on NO production. Kadsulignan H inhibits NO production in BV-2 cells with an IC₅₀ of 14.1 μM .

HY-N10275

Herpotrichone A	Others	Inflammation/Immunology
Herpotrichone A shows potent anti-neuroinflammatory activity in lipopolysaccharide (LPS)-induced BV-2 microglial cells with the half maximal inhibitory concentration (IC₅₀) value of 0.41 μM.

HY-N10274

Herpotrichone B	Others	Neurological Disease Inflammation/Immunology
Herpotrichone B shows potent anti-neuroinflammatory activity in lipopolysaccharide (LPS)-induced BV-2 microglial cells with the half maximal inhibitory concentration (IC₅₀) value of 0.11 μM.

HY-169103

Neuroprotective agent 5	NO Synthase COX Cholinesterase (ChE) Amyloid-β	Neurological Disease Inflammation/Immunology
Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC₅₀=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease .

HY-N12527

Hyperelamine A	NF-κB	Others
Hyperelamine A (compound 5) is a polycyclic polyprenylated acylphloroglucinols (PPAPs). Hyperelamine A exhibits inhibitory activity against LPS-activated NO production in BV-2 cells via TLR-4/NF κB signaling .

HY-N3473

Isomaculosidine	NO Synthase	Neurological Disease
Isomaculosidine is an alkaloid that can be isolated from D. dasycarpus. Isomaculosidine can inhibit nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated BV2 microglial cells .

HY-167853

KR-31080 SK-1080	Angiotensin Receptor	Metabolic Disease
KR-31080 is an derivative of imidazo [4,5-b] pyridine. KR-31080 inhibits angiotensin II receptor. KR-31080 inhibits the NO production in LPS-stimulated BV-2 cells at a concentration of 2 μm with inhibition of 8.3% .

HY-P10350

PapRIV	NF-κB	Neurological Disease Inflammation/Immunology
PapRIV is an agonist of **BV-2 microglial cells*, capable of activating microglial cells* through an NF-κB-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier .

HY-155762

Anti-neuroinflammation agent 1	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype .

HY-N2968

Bullatantriol (+)-Bullatantriol	Others	Inflammation/Immunology
Bullatantriol ((+)?-?Bullatantriol) can be isolated from the roots of Homalomena aromatica. Bullatantriol can promote the proliferation and differentiation of osteoblasts. Bullatantriol also inhibits LPS-induced NO production in BV2 cells .

HY-153690

Progranulin modulator-1	Others	Others
Progranulin modulator-1 (Compound 60) is an orally active enhancer of progranulin (PGRN) secretion. Progranulin modulator-1 enhances the potency of BV-2 cell to increase PGRN levels, has inhibitory effect on hERG and Low cytotoxicity, the PGRN EC₅₀ and hERG IC₅₀ were 83 and 3100 nM, respectively .

HY-138050

Nyasol (-)-Nyasol; (Z)-Hinokiresinol; cis-Hinokiresinol	NO Synthase Bacterial Fungal Parasite Leukotriene Receptor	Infection Inflammation/Immunology
Nyasol ((-)-Nyasol) is an active compound that has antifungal, antibacterial, antileishmanial, hyaluronidase inhibition activities. Nyasol inhibits LTB4 binding to human neutrophils. Nyasol suppresses neuroinflammatory response through the inhibition of I-κB degradation in LPS (HY-D1056)-stimulated BV-2 microglial cells .

HY-146168

Nrf2 activator-5	Keap1-Nrf2	Inflammation/Immunology
Nrf2 activator-5 (compound 1) is a potent Nrf2 activator that can attenuate H₂O₂-induced oxidative stress and LPS-stimulated inflammation in BV-2 microglial cells. Nrf2 activator-5 exhibits antioxidant and anti-inflammatory activities .

HY-N7018

20-Hydroxyganoderic Acid G	Others	Inflammation/Immunology
20-Hydroxyganoderic Acid G is a lanostane triterpenoid obtained from the EtOH extract of fruiting bodies of the Ganoderma curtisii. 20-Hydroxyganoderic Acid G inhibits BV-2 microglia cells activated by LPS with an IC₅₀ of 21.33 μM. 20-Hydroxyganoderic Acid G has therapeutic potential in the agent discovery of nerve inflammation diseases associated with microglia activated by LPS .

HY-155850

CIAC001	Pyruvate Kinase	Neurological Disease
CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. CIAC001 inhibits LPS-induced proinflammatory nitric oxide (NO) production and protects immunologically active BV-2 cells (IC₅₀=2.5 μM). CIAC001 also has anti-neuroinflammation in mouse models and inhibits chronic morphine-induced addiction .

HY-N2259

Curcumenol 3 Publications Verification (+)-Curcumenol	Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
Curcumenol ((+)-Curcumenol) is a potent CYP3A4 inhibitor with an IC₅₀ of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities. Curcumenol ((+)-Curcumenol) suppresses Akt-mediated NF-κB activation and p38 MAPK signaling pathway in LPS-stimulated BV-2 microglial cells .

HY-N4190

Britannilactone diacetate 1,6-O,O-Diacetylbritannilactone; Di-O-acetylbritannilactone	NO Synthase	Neurological Disease Inflammation/Immunology
Britannilactone diacetate (1,6-O,O-Diacetylbritannilactone; Compound 2) exhibits potential NO inhibition effect. Britannilactone diacetate exhibits activity against NO production induced by LPS in BV-2 microglial cells with the EC₅₀ value of 6.3 μM. Britannilactone diacetate exhibits a favorable blood-brain barriers (BBB) penetration and absorption, distribution, metabolism, excretion, and toxicity (ADMET) property .

HY-149202

UT-11	PGE synthase	Inflammation/Immunology
UT-11 is a potent and brain-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with IC₅₀s of 0.10 μM and 2.00 μM for inhibiting PGE₂ production in human (SK-N-AS) and murine (BV2) cells, respectively .

HY-N11657

Sanggenon A Sanggenone A	NF-κB Keap1-Nrf2	Inflammation/Immunology
Sanggenon A (Sanggenone A) exerts anti-inflammatory effects by regulating NF-κB and HO-1/Nrf2 signaling pathways in BV2 and RAW264.7 cells. Sanggenon A markedly inhibits the Lipopolysaccharide (LPS; HY-D1056)-induced production of nitric oxide .

HY-101364

CHPG	mGluR NF-κB ERK Akt	Cardiovascular Disease Inflammation/Immunology
CHPG is a selective mGluR5 agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways .

HY-101364A

CHPG sodium salt	mGluR NF-κB ERK Akt	Neurological Disease Inflammation/Immunology
CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells . CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways. .

HY-N8371

Shizukaol B	NO Synthase COX Interleukin Related TNF Receptor	Inflammation/Immunology
Shizukaol B is a lindenane-type dimeric sesquiterpene, used to be isolated from the whole plant of Chloranthus henryi. Shizukaol B has anti-inflammatory effect against lipopolysaccharide (LPS)-induced activation of BV2 microglial cells. Shizukaol B inhibits iNOS and COX-2, and suppresses NO production, TNF-α, and IL-1β expression .

HY-168091

YM-I-26	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
YM-I-26 is a selective NLRP3 inflammasome inhibitor. YM-I-26 enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells and inhibits the production of IL-1β and IL-10. YM-I-26 can be used to study the immunomodulatory activity associated with inflammation .

HY-146005

Tau-aggregation and neuroinflammation-IN-1	Microtubule/Tubulin	Neurological Disease Inflammation/Immunology
Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats .

HY-N8090

(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid	Others	Inflammation/Immunology
(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid, a lanostane triterpenoids, exhibits obvious NO inhibitory activity on n LPS-induced BV-2 microglia cells with an IC₅₀ of 9.55 uM. (3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid has anti-inflammatory activities .

HY-N8936

Narchinol B	Others	Inflammation/Immunology
Narchinol B (Compound 4) is a sesquiter penoid compound. Narchinol B has anti-inflammatory effects. Narchinol B works by inhibiting proinflammatory mediators, including prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) proteins, as well as proinflammatory cytokines, such as interleukin-1b, IL-6, and tumor necrosis factor-α (TNF-α). Narchinol B significantly inhibits LPS-induced overproduction of NO in BV2 cells (IC₅₀=2.43 μM) .

HY-161925

sTGFBR3 antagonist 1	Others	Neurological Disease Inflammation/Immunology
sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC₅₀ of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research .

HY-N10458

Asperbisabolane L	NF-κB	Inflammation/Immunology
Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the NF-κB-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .

HY-152506

Antioxidant agent-8	Amyloid-β	Neurological Disease
Antioxidant agent-8 is an orally active inhibitor of Aβ_1-42 deposition. Antioxidant agent-8 inhibits fibril aggregation (IC₅₀=11.15 µM) and promotes fibril disaggregation (IC₅₀=6.87 µM). Antioxidant agent-8 also inhibits Cu ²⁺-induced Aβ_1-42 fibril aggregation (IC₅₀=3.69 µM) and promotes Cu ²⁺-induced Aβ_1-42 fibril disaggregation (IC₅₀=3.35 µM). Antioxidant agent-8 has antioxidant activity, anti-inflammatory activity, biosafety, blood-brain barrier permeability and neuroprotective effect .

HY-10512S

AR-A014418-d3 AR 0133418-d₃; GSK 3β inhibitor VIII-d₃; AR 014418-d₃	Isotope-Labeled Compounds GSK-3	Metabolic Disease Cancer
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM)[1].

HY-110003

Arachidonylcyclopropylamide ACPA	Cannabinoid Receptor	Neurological Disease
Arachidonylcyclopropylamide (ACPA) is a potent and selective CB1 receptors agonist. Arachidonylcyclopropylamide inhibits forskolin-stimulated cAMP production in CHO cells transfected with human cannabinoid CB1 receptors (IC₅₀=2 nM) .

HY-147512

CB1/2 agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB1/2 agonist 1 is a potent and cross the blood-brain barrier CB1/2 agonist with EC₅₀s of 56.15, 11.63 nM for CB1R and CB2R, respectively. CB1/2 agonist 1 reduces glutamate release and LPS-induced activation of microglial cells. CB1/2 agonist 1 shows anti-inflammatory and antinociceptive effects. CB1/2 agonist 1 has the potential for the research of multiple sclerosis .

Cat. No.	Product Name	Target	Research Area